Skip to main content
NUTRITION 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Food Systems

Global and Public Health Nutrition

Session: What is the Role of Alternative Proteins in Safely, Equitably, and Sustainably Nourishing 9 Billion People by 2050? (Sponsored Satellite Program)

Panel Discussion - What is the Role of Alternative Proteins in Safely, Equitably, and Sustainably Nourishing 9 Billion People by 2050? (Sponsored Satellite Program)

Sunday, July 23, 2023
7:25 AM – 7:40 AM ET
Location:  Republic Ballroom

Sponsored by Sight and Life Foundation

    Chair(s)

  • JB

    Jacquelyn R. Bedsaul, PhD (she/her/hers)

    Nutritional Immunologist
    Sight and Life Foundation
    Lothian, Maryland, United States

    Disclosure(s): No relevant financial relationship(s) with ineligible companies to disclose.

  • Klaus Kraemer, PhD

    President; Adjunct Professor
    Sight and Life; Johns Hopkins Bloomberg School of Public Health
    Basel, United States

    Disclosure(s): dsm firmenich: Grant/Research Support (Ongoing)

    • Speaker(s)

  • Richard Semba, MD, M.A., M.P.H.

    Professor of Ophthalmology
    Johns Hopkins School of Medicine
    Baltimore, Maryland, United States

    Disclosure(s): No relevant financial relationship(s) with ineligible companies to disclose.

  • Anna Lartey, PhD

    Professor
    University of Ghana
    Legon, Greater Accra, Ghana

    Disclosure(s): No relevant financial relationship(s) with ineligible companies to disclose.

  • Ty R. Beal, PhD

    Research Advisor, Knowledge Leadership
    GAIN
    Phoenix, Arizona, United States

    Disclosure(s): No relevant financial relationship(s) with ineligible companies to disclose.

  • HT

    Hannah Theobald, PhD (she/her/hers)

    Head of Nutrition
    Quorn Foods
    Epsom, England, United Kingdom

    Disclosure(s): GlaxoSmithKline: Stock Shareholder (excluding mutual funds) (Ongoing)

Disclosure(s):
Jacquelyn R. Bedsaul, PhD: No relevant financial relationship(s) with ineligible companies to disclose.
Klaus Kraemer, PhD: dsm firmenich: Grant/Research Support (Ongoing)
Richard Semba, MD, M.A., M.P.H.: No relevant financial relationship(s) with ineligible companies to disclose.
Anna Lartey, PhD: No relevant financial relationship(s) with ineligible companies to disclose.
Ty R. Beal, PhD: No relevant financial relationship(s) with ineligible companies to disclose.
Hannah Theobald, PhD: GlaxoSmithKline: Stock Shareholder (excluding mutual funds) (Ongoing)